Viking Therapeutics Publicizes Initiation of Section 1 Learn about to Review Oral Formula of Twin GLP-1/GIP Receptor Agonist VK2735
Increasing Possible Alternatives for VK2735 with Extremely Differentiated Dosage Choices Expected knowledge in 2H2023 San Diego, March 28, 2023 /PRNewswire/ — Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical corporate targeted at the building of latest remedies for metabolic and endocrine issues, these days introduced that it has initiated a Section 1 medical learn. … Read more